Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Sep - Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015.
Source: Bse
Tatva Chintan Pharma Chem Limited (TATVA)
Small CapIndustrials stocks · Small cap · NSE
Tatva Chintan Pharma Chem Limited operates in Specialty Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Official result overlay30 Sept 2026 · nse-xbrl
Latest result19 Oct, 03:52 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)
Technical timing lens
Trend score and candlestick chart
70Bullishfull bull SMA stack · SMA20 +11.9% / mo · MACD + · near 52W high
Stock trend: 84
Sector RS: 50
Sector 3M: -6.3% vs Nifty 500 -5.6%
Industrials FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
TATVAD candles · FIT view+49.9%Latest close ₹1903.40 on 2026-10-19
Bar
-2.1%
RSI
57
MACD hist
5.26
52W pos
89%
2026-10-19O ₹1944.00H ₹1992.90L ₹1847.50C ₹1903.40Vol 1.4L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
TATVANifty India ManufacturingNifty 500
- TATVA
- +11.1%
- Nifty 500
- -5.6%
- Nifty India Manufacturing
- -5.8%
- Vs Nifty 500
- +16.6 pp
Chart stats
19 Oct 2026- From 52W high
- -5.2%
- 52W range position
- 89%
- ATR (14)
- 5.2%
- Volume vs 20D
- 1.49x
- Avg traded value
- ₹18.3 Cr
- 20D price channel
- ₹1,682.9 - ₹2,008.7
₹2,008.7
₹1,044.1 - ₹2,008.7
₹98
Latest completed session
20-session average
52.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED19
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +75.3% · PAT +114.5% YoY
Technical
Bullish70
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1191.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence67
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Sept 2026
Excellent · 100/100Rev +75% YoY · PAT +115% YoY · margin expansion · +30% QoQ · operating leverage
Filed 19 Oct 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹217.3 Cr | +75.3% | +30.1% |
| EBITDA | ₹40.7 Cr | +85.0% | +26.0% |
| Operating margin | 18.7% | +72 bps | -61 bps |
| PAT | ₹21.5 Cr | +114.5% | +34.2% |
| PAT margin | 9.9% | +181 bps | +30 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 70.76
- P/B
- 5.39
- EV/EBITDA
- 29.64
- Market Cap
- 4452.43Cr
Profitability
- ROE
- 5.54%
- ROCE
- 7.18%
- ROA
- 5.08%
- Dividend Y
- 0.11%
Growth (CAGR)
- Revenue 5Y
- 11.00%
- EPS 5Y
- -4.00%
- Revenue 3Y
- 6.00%
- EPS 3Y
- -5.00%
Balance Sheet
- Debt/Equity
- 0.15
- Interest Coverage
- 21.60×
- Altman Z
- 8.25
- Book Value
- 334.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- 31.00 Cr
- EPS TTM
- 26.90
Shareholding
- Promoter Hold
- 72.02%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 91%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 506+32.1% vs prev
Net Profit
₹ CrLatest: 42.0+600.0% vs prev
Return on Equity
%Latest: 5.4+564.2% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bullish setupTrend is constructive — long-term uptrend intact. RSI 57.
- Price > SMA20 > SMA50 > SMA200 — full bullish stack.
- SMA20 rising (~10.6% over last month) — short-term momentum positive.
- RSI(14) at 57 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 5% off 52W high · 82% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
86
RS percentile
Stage 2 UptrendEstablished S2
1M return
+7.5%
3M return
+11.1%
6M return
+44.0%
1Y return
+41.1%
RS 1D
-2
RS 20D
-5
Sector rank
#2
Industry rank
#9
Stage evidence
- Price is 32.0% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +6.5%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
28 Jul 2026
S2 age
58 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 194.08-1.08%
RS vs Nifty 500194
Valuation & peers
U-Score 19 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 19 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth4/25
Quality0/20
Balance Sheet10/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
19
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
19/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 10/15 to the score.
- Growth contributes 4/25 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -1191.2%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
70.8
PB
5.4
EV/EBITDA
29.6
ROE
5.5%
ROCE
7.2%
FCF Yield
—
Debt/Equity
0.1
MoS
-1191.2%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE. Earnings growth is much stronger than revenue growth; verify sustainability.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
19
Previous: 19
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1191.2%
Previous: -1191.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
20
20
20
20
20
20
20
20
20
19
19
19
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹449.61
-323.3% MoS
Growth-justified P/E
5.5
Growth-justified Value
₹147.41
-1191.2% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
PAR
Small
Par Drugs And Chemicals Limited
Specialty Chemicals
match 164
43
10.5
9.9%
-15%
WATCHLIST
FCL
Small
Fineotex Chemical Limited
Specialty Chemicals
match 163
33
51.4
13.5%
-34%
WATCHLIST
PAUSHAKLTD
Small
Paushak Limited
Specialty Chemicals
match 162
24
43.1
7.0%
-419%
OVERVALUED
JGCHEM
Small
J.G.Chemicals Limited
Specialty Chemicals
match 161
43
31.8
13.2%
+19%
WATCHLIST
IGPL
Small
IG Petrochemicals Limited
Specialty Chemicals
match 161
30
20.9
0.2%
-3623%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Tatva Chintan Pharma Chem Limited operates in Specialty Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Sept 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
67Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 50th percentile within Industrials. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
88 docs text-extracted · 40 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
52nd percentile
overall median 67 · Industrials: 50th pctile, median 68 · Small: 56th pctile, median 66
Evidence depth
Financial-only
88 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
48
watch · capital discipline
Results
80
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 72%.
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸Only 0 years of positive FCF.
- ▸ROCE is low at 7.2%.
- ▸ROE is low at 5.5%.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Tatva Chintan Pharma Chem Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 Sep - Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015.
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 8 Sep - CRISIL upgraded Tatva Chintan’s bank facilities rating to A-/Stable and A2+ for Rs245 crore facilities.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Aug - Newspaper Advertisement - Disclosure under Regulation 30, 44 and 47 of the SEBI (LODR) Regulations, 2015, as ....
Source: Bse
Annual report
Business Responsibility and Sustainability Reporting (BRSR) 27 Aug - Tatva Chintan submitted its FY2025-26 BRSR with annual report under SEBI Regulation 34(2)(f).
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Aug - Newspaper Advertisement - Disclosure under Regulation 30 and 47 of SEBI (LODR) Regulations, 2015, as amended. ....
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 Aug - Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Aug - Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Jul - Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of ....
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Jun - Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.